Search
Dibotermin alfa
go.drugbank.com/drugs/DB11639ApprovedInvestigationalIn a prospective clinical study of patients with an open tibial fracture, administration of dibotermin alfa resulted in faster fracture- or wound-healing, significantly fewer secondary invasive interventions … Dibotermin alfa was approved by the EMA in 2002 as Inductos for implantation matrix. In 2004, it was approved by the FDA and is marketed as Infuse.
Vepdegestrant
go.drugbank.com/drugs/DB19006ApprovedInvestigational[A275507, A275509] In a global, randomized Phase III clinical trial (VERITAC-2), vepdegestrant was clinically evaluated and compared against the injectable selective estrogen receptor degrader (SERD) [ … Vepdegestrant is a potent, selective, and orally bioavailable PROteolysis TArgeting Chimera (PROTAC) small molecule estrogen receptor (ER) degrader.
Difelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigationalDifelikefalin (CR845) is an agonist of kappa opioid receptors (KORs) useful in the treatment of pruritus secondary to chronic kidney disease. KORs were first associated with itching in 1984. … [A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes
Terpin hydrate
go.drugbank.com/drugs/DB13163ApprovedWithdrawnIt was popular in the United States since the late nineteenth century, but was removed from marketed medications in the 1990s after FDA stated that "based on evidence currently available, there are inadequate … Terpin hydrate is an expectorant, commonly used to loosen mucus and ease congestion in patients presenting with acute or chronic bronchitis, and related pulmonary conditions.
Ciltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigationala range of symptoms including bone pain, hematologic abnormalities, and end-organ damage. … [A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development
Rimantadine
go.drugbank.com/drugs/DB00478ApprovedAn RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.
Tezepelumab
go.drugbank.com/drugs/DB15090ApprovedInvestigational[L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712] … [A243769] Conversely, tezepelumab, which targets the upstream master regulator TSLP, has the potential to be effective across asthma endotypes.
Finerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigationalFinerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart … [A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449]
Avacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigational[A240249, A240254] Despite complex pathophysiology, studies over the past ~2 decades have identified a key role for the alternative complement pathway and, in particular, the interaction between the anaphylatoxin … [A240254, A240259, A240264, A240269] Avacopan (formerly CCX168) is an allosteric C5aR antagonist indicated for use in AAV.
Catumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnIts market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. … Catumaxumab was approved for market in Canada in May 2012 for the same condition [FDA Label]. It is currently available under the brand name Removab.